Lead sponsor
Beijing Dongfang Biotech Co., Ltd.
4 GLP-1 and incretin trials led. Source: ClinicalTrials.gov, as of July 1, 2026.
4
Trials led
2
Active
924
Total enrollment
3
Sites
Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.
Portfolio
How this sponsor's trials break down
Trials by phase
Phase 1
2
Phase 3
2
Trials by status
Active, not recruiting
2
Completed
1
Unknown
1
Trials led
TrialKey I/E criterionPhaseStatusEnrollment
A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Dulaglutide in Combination Therapy Diabetes Mellitus Type 2 Patients With MetforminBMI 18.5-35Ph 3Active, not recruiting600
A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Placebo in T2DM PatientsBMI 18.5-35Ph 3Active, not recruiting270